FDA OKs First-Line Immunotherapy in Liver Cancer

<![CDATA[]]>(MedPage Today) — The FDA on Friday approved the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq) for the first-line treatment of unresectable or metastatic liver cancer, in combination with bevacizumab (Avastin), an inhibitor of the…

Source link

Related posts

Historical data are not relevant to the diagnostic performance of ultrasound in HCC surveillance


Human β-defensin-3 reduces excessive autophagy in intestinal epithelial cells and in experimental necrotizing enterocolitis


Physician burnout rate increases, broad-based approaches alleviate causes


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World